Key result
After intra-arterial administration of ioversol, the incidence of post-contrast acute kidney injury was highly variable (1.5-35.5%) but appeared comparable to other iodinated contrast media, with an overall adverse drug reaction incidence of 1.6%.
Why the study?
What is the incidence of adverse drug reactions and post-contrast acute kidney injury after intra-arterial administration of ioversol?
Population
8,373 patients across 28 studies (including two pediatric studies) exposed to intra-arterial ioversol
Comparison
Intra-arterial administration of ioversol vs Other iodinated contrast media (ICM) or none
Design
Systematic_review
Authors
Loading...
IA ioversol shows low, comparable ADR/PC-AKI rates to other ICM; reinforces safety profile while highlighting heterogeneity for standardized trials.
Systematic Review (n=8,373)
What is the incidence of adverse drug reactions and post-contrast acute kidney injury after intra-arterial administration of ioversol?
Intra-arterial administration of ioversol is associated with a low overall rate of adverse drug reactions (1.6%) and a highly variable incidence of post-contrast acute kidney injury that appears comparable to other iodinated contrast media.
Molen et al. (2022) conducted a systematic review in Patients undergoing intra-arterial administration of contrast media (n=8,373). Intra-arterial administration of ioversol vs. Other iodinated contrast media was evaluated on Incidence of post-contrast acute kidney injury (PC-AKI) and adverse drug reactions (ADRs). After intra-arterial administration of ioversol, the incidence of post-contrast acute kidney injury was highly variable (1.5-35.5%) but appeared comparable to other iodinated contrast media, with an overall adverse drug reaction incidence of 1.6%.